Tamoxifen citrate
Inquiry
| Post Date: | Sep 21,2016 |
| Expiry Date: | Sep 21,2017 |
| Detailed Description: |
Cas No. :10540-29-1
Quantity: 1Kilograms Specs:alisa@pharm-china.com Price:1 USD Kilograms Payment Method: Western Union, MoneyGram, Bank transfer, Bite Tamoxifen citrate 1. Quick Details: Product name: Tamoxifen citrate Other name: Nolvadex CAS: 10540-29-1 EINECS: 259-415-2 Molecular formula: C32H37NO8 Molecular weight: 563.64 Melting point: 140-144 °C Assay: 99% Appearance: White crystalline powder. Package: 1kg/aluminium foil bag or as required Minimum order quantity: 10g Shipping: By express courier Shipping leading time: Within 24 hours after receiving the payment Payment options: Western Union, Moneygram, Bank transfer, paypal 2. We Guarantee: a. Fast Delivery: 3 work days after received payment. b. Free Resending: For long term cooperation, we guarantee all our customers will get their stuffs. c. Long Term Cooperation Discount: 5% DISCOUNT for our regular customers. 3. Hot sell: Injection liquid Name Specification Deca 200 200mg/ml Deca 250 250mg/ml Anadrol 50 50mg/ml Anavar 50 50mg/ml Anomass 400 400mg/ml Boldenone Acetate 100 100mg/ml (Boldenone Cypionate) 200mg/ml (Boldenone undecylenate) 300mg/ml Clomid 50 50mg/ml Cypoject 250 (Testosterone Cypionate) 600mg/ml Dianabol 250 250mg/ml Durabolin 250 250mg/ml Enanject 250 (Testosterone Enanthate) 250mg/ml Enanject 600 (Testosterone Enanthate) 600mg/ml Femara 5 5mg/ml NPP 200 200mg/ml (Nandrolone Cypionate) 200mg/ml Nolvadex 20 20mg/ml Winstrol 50 50mg/ml Propionat 100 (Testosterone Propionate) 100mg/ml Propionat 200 (Testosterone Propionate) 200mg/ml Sustanon 200 200mg/ml Sustanon 250 250mg/ml Sustanon 300 300mg/ml Sustanon 400 400mg/ml Undecanoate 500 (Testosterone Undecanoate) 500mg/ml Trenabol 100 100mg/ml Trenabolic 80 (Trenbolone Acetate) 80mg/ml Trenabolic 100 (Trenbolone Acetate) 100mg/ml Trenabolic 200 (Trenbolone Acetate) 200mg/ml Trenaject 60 (Trenbolone enanthate) 60mg/ml Trenaject 100 (Trenbolone Enanthate) 100mg/ml Trenaject 150 (Trenbolone Enanthate) 150mg/ml Trenaject 200 (Trenbolone Enanthate) 200mg/ml Parabolone 50 (Tren hex) 50mg/ml Masteron 100 (Drostanolone Propionate) 100mg/ml Masteron 200 (Drostanolone Enanthate) 200mg/ml Primoject 100 (Methenolone Enanthate) 100mg/ml TMT Blend 375 (Trenbolone Enanthate 125mg/ml; Drostanolone Enanthate 125mg/ml;Testosterone Enanthate 125mg/ml) TM Blend 500(Trenbolone Enanthate 250mg/ml Drostanolone Enanthate 250mg/ml) Raw Powder 1 Testosterone enanthate CAS: 315-37-7 2 Testosterone acetate CAS: 1045-69-8 3 Testosterone propionate CAS: 57-85-2 5 Testosterone cypionate CAS: 58-20-8 6 Testosterone phenylpropionate CAS: 1255-49-8 7 Testosterone isocaproate CAS: 15262-86-9 8 Testosterone decanoate CAS: 5721-91-5 9 Testosterone Sustanon 250 10 Testosterone undecanoate CAS: 5949-44-0 11 Turinabol (4-Chlorotestosterone acetate) CAS: 855-19-6 12 Oral turinabol CAS: 2446-23-3 13 Stanolone (androstanolone) CAS: 521-18-6 14 Nandrolone Decanoate (DECA) CAS: 360-70-3 15 Nandrolone Cypionate CAS: 601-63-8 16 Nandrolone Phenypropionate (Durabolin) CAS: 62-90-8 17 Boldenone Undecylenate (Equipoise) CAS: 13103-34-9 18 Boldenone Acetate CAS :2363-59-9 19 Drostanolone Propionate (Masteron) CAS: 521-12-0 20 Drostanolone Enanthate CAS: 472-61-1 21 Superdrol Powder (methyl-drostanolone) CAS: 3381-88-2 22 Trenbolone Acetate (Finaplix H/Revalor-H) CAS: 10161-34-9 23 Trenbolone Enanthate (parabolan) CAS: 10161-33-8 24 Trenbolone Hexahydrobenzyl Carbonate CAS: 23454-33-3 25 Epiandrosterone CAS: 481-29-8 26 Dehydroisoandrosterone Acetate CAS: 853-23-6 27 CAS: 566-19-8 28 Methenolone Enanthate (Primobolan) CAS: 303-42-4 29 Methenolone Acetate CAS: 434-05-9 30 Methandrostenolone(Dianabol) CAS: 72-63-9 31 Tamoxifen Citrate (Nolvadex) CAS: 54965-24-1 32 Clomiphene citrate CAS: 50-41-9 33 Toremifene citrate CAS: 89778-27-8 34 Letrazole(Femara) CAS: 112809-51-5 35 vardenafil CAS: 831217-01-7 36 Dapoxetine CAS: 119356-77-3 37 Dapoxetine HCl CAS: 1071929-03-7 38 Dutasteride CAS: 164656-23-9 39 Finasteride CAS: 98319-26-7 40 Yohimbine HCl CAS: 65-19-0 MGF (2mg/vial) CJC-1295DAC 863288-34-0 (2mg/vial) PT-141 32780-32-8 (10mg/vial) Melanotan-II (10mg/vial) GHRP-6 87616-84-0 (5mg/vial) Hexarelin 140703-51-1 (2mg/vial) Oxytocin (2mg/vial) pentadecapeptide BPC 157 (2mg/vial) Triptorelin Acetate (2mg/vial) Tesamorelin 106612-94-6 (2mg/vial) Selank (5mg/vial) Carbetocin Acetate 37025-55-1 (1G / foil bag) EGF 62253-63-8 (1KG / fluorinated bottle) Thymosin α1 Acetate 62304-98-7 (1G / polypeptide tube) PEG-MGF (2mg/vial) CJC-1295 (2mg/vial) Melanotan-I (10mg/vial) GHRP-2 158861-67-7 (5mg/vial) Ipamorelin 170851-70-4 (2mg/vial) Sermorelin 86168-78-7 (2mg/vial) TB500 75591-33-4 (2mg/vial) Fragment 176-191 (2mg/vial) Gonadorelin Acetate 34973-08-5 (2mg/vial) DSIP 62568-57-4 (2mg/vial) AOD-9604 221231-10-3 (1G / foil bag) Desmopressin acetate 16789-98-3 (1G / foil bag) Eptifibatide 188627-80-7 (1G / foil bag) Hot selling list Blend 1 0.5mg cjc with dac + 0.5mg hexarelin + 1mg ipamorelin Blend 2 Ghrp-6 1mg+Ipamorelin 1mg+Cjc-1295 1mg+Mgf 500mcg Blend 3 ... Your requirement 4. More Information About Tamoxifen citrate: Tamoxifen Citrate is a Selective Estrogen Receptor Modulator (SERM) that was created in 1961 by ICI now known as AstraZenaca. There are numerous brands including generic forms of Tamoxifen Citrate on the market, but Nolvadex is the most well known. Often referred to as an anti-estrogen, Tamoxifen Citrate is actually both an antagonist and agonist. This means it will act as an anti-estrogen in certain areas of the body while acting as an estrogen in other areas. Tamoxifen Citrate has been used medically for decades and has been highly successful in breast cancer treatment, specifically hormone-responsive breast cancer. It is also a medication that is used by many anabolic steroid users, but it is not a steroid. This is a drug steroid users will sometimes use during steroid use to help with estrogenic related side effects brought on by specific steroids. However, it is most commonly used during Post Cycle Therapy (PCT). PCT is the 3-6 week period following steroid use that is implemented in order to help with natural testosterone production that is suppressed during anabolic steroid use. Tamoxifen Citrate is a nonsteroidal agent which has demonstrated potent antiestrogenic properties in animal test systems. The antiestrogenic effects may be related to its ability to compete with estrogen for binding sites in target tissues such as breast. Tamoxifen inhibits the induction of rat mammary carcinoma induced by dimethylbezanthracene (DMBA) and causes the regression of already established DMBA-induced tumors. In this rat model, tamoxifen appears to exert its antitumor effects by binding the estrogen receptors. It is also recognized that tamoxifen displays estrogenic like effects on several sites including the endometrium, bone and lipids. In cytosols derived from human breast adenocarcinomas, tamoxifen competes with estradiol for estrogen receptor protein. Tamoxifen is extensively metabolized after oral administration. Studies in women reviewing 20 mg of 14C tamoxifen have shown that approximately 65% of the administered dose was excreted from the body over a period of 2 weeks with fecal excretion as the primary route of elimination. The drug was excreted mainly as polar conjugates, with unchanged drug and unconjugated metabolites accounting for less than 30% of the total fecal radioactivity. N-desmethyl tamoxifen was the major metabolite found in patients plasma. The biological activity of N-desmethyl tamoxifen appears to be similar to tamoxifen. 4-Hydroxytamoxifen and a side chain primary alcohol derivative of tamoxifen have been identified as minor metabolites in plasma. Following a single oral dose of 20 mg tamoxifen, an average peak plasma concentration of 40 ng/mL (range 35 to 45 ng/mL) occurred approximately 5 hours after dosing. The decline in plasma concentrations of tamoxifen is biphasic with a terminal elimination half-life of about 5 to 7 days. The average peak plasma concentration for N-desmethyl tamoxifen is 15 ng/mL (range 10 to 20 ng/mL). Chronic administration of 10 mg tamoxifen given twice daily for three months of patients results in average steady-state plasma concentrations of 120 ng/mL (range 67-183 ng/mL) for tamoxifen and 336 ng/mL (range 148-654 ng/mL) for N-desmethyl tamoxifen. The average steady-state plasma concentrations of tamoxifen and N-desmethyl tamoxifen after administration of 20 mg tamoxifen once daily for three months are 122 ng/mL (range 71-183 ng/mL) and 353 ng/mL (range 152-706 ng/mL, respectively. After initiation of therapy, steady state concentrations for tamoxifen are achieved in about 4 weeks and steady state concentrations for N-desmethyl tamoxifen are achieved in about 8 weeks, suggesting a half-life of approximately 14 days for this metabolite. Clinical Studies: The Early Breast Cancer Trialists Collaborative Group (EBCTCG) conducted worldwide overviews of systemic adjuvant therapy for early breast cancer in 1985 and again in 1990. In 1992, 10-year outcome data were reported for 29,892 women in 40 randomized trials of adjuvant tamoxifen using doses of 20-40 mg/day for 1-5+ years (median 2 years). Fifty-one percent were entered into trials comparing tamoxifen to no adjuvant therapy and 49% were entered into trials of tamoxifen in combination with chemotherapy vs. the same chemotherapy alone. Twenty-nine percent were < 50 years of age and 71% were >/= to 50 years. Fifty-seven percent were node-positive and 43% were node-negative. Fifty percent of the tumors were estrogen receptor (ER) positive (>/= to 10 fmol/mg), 18% were ER poor (< 10 fmol/mg), and 32% were ER unknown. The overall recurrence-free survival at 10 years of follow-up was 51.2% for tamoxifen versus 44.7% for control (logrank 2p < 0.00001). Overall survival at 10 years was 58.8% for tamoxifen versus 52.6% for control (logrank 2p < 0.000001). Both the absolute risk of relapse and the absolute benefit of treatment with tamoxifen were greater in women with positive nodes than in women with negative nodes. In women with positive nodes, 10-year recurrence-free survival was 41.9% for tamoxifen versus 33.1% for control (logrank 1p < 0.0002). Ten-year survival was 50.4% for tamoxifen vs. 42.2% for control (lorank 1p < 0.00001). In women with negative nodes, recurrence-free survival was 68.1% for tamoxifen vs. 63.1% for control (logrank 1p < 0.00001). Survival at 10 years was 74.5% for tamoxifen vs. 71.0% for control (logrank 1p = 0.0002). The reduction in the annual odds of recurrence with tamoxifen was 12% in women < 50 years of age versus 29% in women >/= to 50 years. Similarly, the reduction in the annual odds of death was 6% versus 20%. The reduction in the annual odds of recurrence with tamoxifen was significantly greater in aer positive (32%) than in ER poor (13%) tumor(1p < 0.00001). The reduction in recurrence and mortality was greater in those studies which used tamoxifen for longer (>/= to 2 years) rather than shorter (< 2 years) periods. There was no indication that doses greater than 20 mg per day were more effective. Two studies (Hubay and NSABP B-09) demonstrated an improved disease-free survival following radical or modified radical mastectomy in postmenopausal women or women 50 years of age or older with surgically curable breast cancer with positive axillary nodes when Tamoxifen Citrate was added to adjuvant cytotoxic chemotherapy. In the Hubay study, Tamoxifen Citrate was added to "low-dose" CMF (cyclophosphamide, methotrexate and fluorouracil). In the NSABP B-09 study, Tamoxifen Citrate was added to melphalan [L- phenylalanine mustard (P)] and fluorouracil (F). In the Hubay study, patients with a positive (more than 3 fmol) estrogen receptor were more likely to benefit. In the NSABP B-09 study in women age 50-59 years, only women with both estrogen and progesterone receptor levels 10 fmol or greater clearly benefited, while there was a nonstatistically significant trend toward averse effect in women with both estrogen and progesterone receptor levels less than 10 fmol. In women age 60-70 years, there was a trend toward a beneficial effect of Tamoxifen Citrate without any clear relationship to estrogen or progesterone receptor status. Three prospective studies (ECOG-1178, Toronto, NATO) using Tamoxifen Citrate adjuvantly as a single agent demonstrated an improved disease-free survival following total mastectomy and axillary dissection for postmenopausal women with positive axillary nodes compared to placebo/no treatment controls. The NATO study also demonstrated an overall survival benefit. 5. Key words: Buy Tamoxifen citrate, Tamoxifen citrate raw powder, Tamoxifen citrate anabolic steroid powder, Tamoxifen citrate price, anabolic steroid powder Tamoxifen citrate, Tamoxifen citrate COA, Tamoxifen citrate manufacturer, Tamoxifen citrate powder, body building steroid Tamoxifen citrate, body building supplement Tamoxifen citrate, Tamoxifen citrate for muscle gaining, Tamoxifen citrate for fat burning, Tamoxifen citrate injection, Tamoxifen citrate semi-finished injection, Tamoxifen citrate steroid raw, Tamoxifen citrate raw material, Tamoxifen citrate fine powder, high purity Tamoxifen citrate powder, Tamoxifen citrate 99% assay, Tamoxifen citrate CAS, Tamoxifen citrate HPCL, Tamoxifen citrate factory 6. Seller's Information: Company: Shanghai Yijing Pharmaceutical Co., Ltd Mob: +OO86-13O26163653 7. How to place an order: Send me an email at the address above, tell me product name and quantity. |
| CAS Registry Number: | 10540-29-1 |
| Synonyms: | ;tamoxifen free base;Genox;Kessar;Nolvadex;Nolvadex-D;Tamoxen;(Z)-2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine;2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine 2-hydroxypropane-1,2,3-tricarboxylate (salt);2-{4-[(1Z)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine;2-{4-[(1E)-1,2-diphenylbut-1-en-1-yl]phenoxy}-N,N-dimethylethanamine; |
| Molecular Formula: | C26H29NO |
| Molecular Weight: | 371.5146 |
| Molecular Structure: | 
|
| Hazard Symbols: |  T:Toxic; |
| Risk Codes: | R45:; R60:; R61:; R64:; |
| Safety Description: | S53:; S45:; |
| Company: | Shanghai Yijing Pharmaceutical Co., Ltd [ China ] |
| Contact: | Alisa |
| Tel: | +86-130-26163653 |
| Fax: | |
| Email: | alisa@pharm-china.com |
-
Disclaimer statement:The information and data included above have been realized by the enterprises and compiled by the staff, and are subject to change without notice to you. The Chemnet makes no warranties or representations whatsoever regarding the facticity, accuracy and validity of such information and data. In order to ensure your interest, we suggest you chose the products posted by our gold suppliers or VIP members.
